biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The vote

<< Previous

Bullboard Posts

Next >>

Comment by zwerp2000on Jan 11, 2023 2:40pm

86 Views

Post# 35216513

RE:RE:The vote

What I do not understand is if this technology is so revolutionary and fantastic, how could a big pharma, or any reputable pharma let it go for essentially nothing. MTP is nothing special at all. Prothena evaluated the technology for years and passed. Chiesi did a deal with BTI several years ago and nothing has come of it.

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season